VERAXA Biotech (NASDAQ: VRXA) has taken a significant step forward in the development of its proprietary BiTAC®-TCE platform after receiving Scientific Advice from Germany’s Paul-Ehrlich-Institute (PEI). The regulatory feedback, announced on July 20, supports the company’s proposed development strategy for its lead BiTAC®-TCE program, providing early guidance on biological rationale, safety assessments, and the non-clinical development plan.
The Scientific Advice procedure allows drug developers to consult with regulatory experts before clinical trials begin, helping to align development strategies with regulatory expectations. For VERAXA, this feedback helps reduce development uncertainty by providing greater clarity on the path forward. The company believes that the advice supports the advancement of its novel therapeutic platform, which is designed to harness bispecific T-cell engagers for cancer treatment.
VERAXA’s lead BiTAC®-TCE candidate has previously generated encouraging preclinical data presented at the 2026 American Association for Cancer Research (AACR) Annual Meeting. The company continues to build a diversified oncology pipeline that includes bispecific T-cell engagers, antibody-drug conjugates (ADCs), and other engineered antibody formats. This latest regulatory milestone follows continued progress in manufacturing and development as VERAXA advances next-generation antibody therapeutics for cancer.
The positive feedback from PEI is a critical step for VERAXA as it prepares its most advanced BiTAC®-TCE candidate for future clinical development. The company’s press release noted that the advice provides early guidance on the biological rationale and non-clinical development strategy, which could streamline the transition into clinical studies. For more details on the announcement, visit this link.
VERAXA Biotech, based in Los Angeles, California, is an emerging leader in designing novel cancer therapies. The company’s pipeline focuses on innovative approaches to immunotherapy, aiming to improve outcomes for patients with cancer. The latest news and updates relating to VRXA are available in the company’s newsroom at this link.
Forward-looking statements in this article involve risks and uncertainties that could cause actual results to differ materially. These include factors set forth in the company’s filings with the SEC, such as its Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. Undue reliance should not be placed on forward-looking statements, and the company undertakes no duty to update this information unless required by law.
